RxDoctor Payments Data

Orvar Jonsson, MD

Advanced Heart Failure and Transplant Cardiology · Sioux Falls, SDNPI 1831302009

Payments from drug & device makers

$1,811,996in general payments, 2019–2025

Across 673 payments — averaging $2692.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$657K
  • Endotronix, Inc.$609K
  • Novartis$220K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$97K
  • Bayer$76K
  • Janssen Research & Development, LLC$63K
  • plus $91K from 22 others

What the payments were for

  • Consulting fees$11,9608%
  • Speaking & faculty fees$104,89974%
  • Travel & lodging$9,8507%
  • Food & beverage$15,04311%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$369,187
Medicare patients
1,920
Services billed
5,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan108$1,341,402
Tyvaso DpiTreprostinil39$895,687
UptraviSelexipag28$654,980
EliquisApixaban459$310,544
AdempasRiociguat17$220,920
EntrestoSacubitril/Valsartan100$80,606
XareltoRivaroxaban93$77,338
Repatha SureclickEvolocumab87$56,141
Ambrisentan13$37,050
JardianceEmpagliflozin46$30,718
Praluent PenAlirocumab42$24,177
Repatha SyringeEvolocumab15$15,041
BrilintaTicagrelor24$13,161
FarxigaDapagliflozin Propanediol15$10,995
Flecainide Acetate156$6,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$49,639$1,996,383136 claims
PfizerEliquis$42$310,544459 claims
BayerAdempas$75,663$220,92017 claims
NovartisEntresto$220,407$80,606100 claims
Johnson & JohnsonXarelto$305$77,33893 claims
Boehringer IngelheimJardiance$33$30,71846 claims
AstraZenecaBrilinta, Farxiga$9,612$24,15639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Sioux Falls

Where these figures come from

Is this you, or does something look wrong? →